



CLINIQUE MÉDICALE VICTOR HUGO

PUBLICATIONS DE L'ÉQUIPE MÉDICALE DU CENTRE JEAN BERNARD

CLASSEMENT DES ARTICLES PUBLIÉS DE 2005 À 2010
(REVUES INDEXÉES AVEC COMITÉ DE LECTURE ET IMPACT FACTOR)

Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, Delmer A, Bordessoule D, Tilly H, Corront B, Allard C, Foussard C, Bosly A, Coiffier B, Gisselbrecht C, **Solal-Celigny P**, Salles G. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prirituximab era: effect of response quality on survival--A study from the groupe d'étude des lymphomes de l'adulte. *J Clin Oncol* 2010 Feb; 28:822-829

Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, **Bourgeois H**. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. *Gynecol Oncol*. 2010 Mar;116(3):312-6

Robak T, Dmoszynska A, **Solal-Celigny P**, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Geisler CH, Montillo M, Zyuzgin I, Ganly PS, Dartigeas C, Rosta A, Maurer J, Mendila M, Saville MW, Valente N, Wenger MK, Moiseev SI. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. *J Clin Oncol*. 2010 Apr; 28:1756-1765

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, **Dupuis O**, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol*. 2010 Apr1; 28(10):1638-44.

Dewas S, Vautravers-Dewas C, Blanchard P, Pointreau Y, **Denis F**, Lacornerie T, Gibon D, Giraud P. Delineation variation of lung cancer in conformal radiotherapy among radiation oncology residents after an educational course: a prospective study. *Cancer Radiother*. 2010 Apr;14(2):103-10

Martin E, Pointreau Y, **Roche-Forestier S**, Barillot I. Normal tissue tolerance to external beam radiation therapy: small bowel. *Cancer Radiother*. 2010 Jul;14(4-5):350-3.

Hayashi D, Lee JC, Devenney-Cakir B, Zaim S, Ounadjela S, **Solal-Celigny P**, Juweid M, Guermazi A. Follicular non-Hodgkin's lymphoma. *Clin Radiol* 2010 May; 65:408-420

Debelleix C, Pointreau Y, Lafond C, **Denis F**, Calais G, Bourhis JH. Normal tissue tolerance to external beam radiation therapy: larynx and pharynx. *Cancer Radiother*. 2010 Jul;14(4-5):301-6. Epub 2010 Jul 2

Bera G, Pointreau Y, **Denis F**, Orain I, **Dupuis O**, Créhange G. Normal tissue tolerance to external beam radiation therapy: esophagus. *Cancer Radiother*. 2010 Jul;14(4-5):327-35. Epub 2010 May 21

Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP, El Yamani A, Cornillon J, Rossi JF, Le Gouill S, Lepeu G, Damaj G, **Solal Celigny P**, Maisonneuve H, Corront B, Vilque JP, Casassus P, Lamy-de-La-Chapelle T, Colonna M, Colombat P. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed Mantle Cell Lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. *Haematologica* 2010 Aug; 95(8):1350-7

Cahu X, Bodet-Milin C, Brissot E, Maisonneuve H, Houot R, Morineau N, **Solal-Celigny P**, Godmer P, Gastinne T, Moreau P, Moreau A, Lamy T, Kraber-Bodere F, Le Gouill S. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. *Ann Oncol*. 2010 Aug 25.

Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? *Int J Hematol*. 2010 Sep;92(2):246-54. Epub 2010 Aug 31. Review.PMID: 20803352



CLINIQUE MÉDICALE VICTOR HUGO

- Morschhauser F, Mounier N, Sebban C, Brice P, **Solal-Celigny P**, Tilly H, Feugier P, Fermé C, Copin MC, Lamy T. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naïve, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). *Cancer*. 2010 Sep 15;116(18):4299-308.
- Bouleuc C, Bredart A, Dolbeault S, **Ganem G**, Coppel L. [How to improve cancer patients' satisfaction with medical information]. *Bull Cancer*. 2010 Oct; 97(10):1173-81
- Ganem G**, Cartron G, Girinski T, Haas RL, Cosset JM, **Solal-Céline P**. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. *Int J Radiat Oncol Biol Phys*. 2010 Nov 15;78(4):975-82.
- Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, Zhi J, Robak T, Moiseev SI, Dmoszynska A, **Solal-Celigny P**, Warzocha K, Loscertales J, Catalano J, Afanasiev BV, Larratt L, Rossiev VA, Bence-Bruckler I, Geisler CH, Montillo M, Wenger MK, Weisser M. Effect of FCGR2A and FCGR3A variants on CLL outcome. *Blood*. 2010 Nov 18;116(20):4212-22.
- F. Denis** et Y Pointreau. Editorial numéro spécial SIRIADE. *Cancer Radiother*. 2010. Nov;14S1:S1
- F. Denis** et Y Pointreau. Radio-anatomy atlas for delineation SIRIADE website: features and 1 year results. *Cancer Radiother*. 2010. Nov;14S1:S2-S5
- D Pasquier, L Peyrodie, **F Denis** et al. Automatic image segmentation for treatment planning in radiotherapy. *Cancer Radiother*. 2010. Nov;14S1:S6-S13
- L Mineur, E Jaegle, Y Pointreau and **F Denis**. Gastric Cancers. *Cancer Radiother*. 2010. Nov;14S1:S84-S93
- C Lafond**, Y Pointreau, C Debelleix, **Denis F**, et al. Oropharyngeal cancers. *Cancer Radiother*. 2010. Nov;14S1:S34-S42
- O Dupuis**, **G Ganem**, G Béra, Y Pointreau, O Pradier, P Martin, X Mirabel and **F Denis**. Esophageal cancers. *Cancer Radiother*. 2010. Nov;14S1:S74-S83
- Y Pointreau, A Ruffier Loubière, **F Denis**, I Barillot. Cervix cancers. *Cancer Radiother*. 2010. Nov;14S1:S147-S153
- Y Pointreau, G Bernadou, **F Denis**, I Barillot. Endometrial cancers. *Cancer Radiother*. 2010. Nov;14S1:S154-S160
- Y Pointreau, S Klot, **F Denis**, C Durdoux. Bladder cancers. *Cancer Radiother*. 2010. Nov;14S1:S189-S197
- F Drouet, X Cahu, Y Pointreau, **F Denis** and M Mahé. Hodgkin's Lymphomas. *Cancer Radiother*. 2010. Nov;14S1:S198-S209
- F Drouet, X Cahu, Y Pointreau, **F Denis** and M Mahé. Non-Hodkin's Lymphomas. *Cancer Radiother*. 2010. Nov;14S1:S210-S229
- Pham CT, Clarençon F, **Ganem G**, Cormier E, Guermazi Y, Rose M, Chiras J. Spinal cervical metastasis from a glioblastoma multiforme treated by percutaneous vertebroplasty: A case report. *J Neuroradiol*. 2010 Nov 18. [Epub ahead of print]
- Joly F, Sevin E, Lortholary A, Priou F, Paitel JF, Fabbro M, Henry-Amar M, Hamond K, **Bourgeois H**. Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial. *Gynecol Oncol*. 2010 Mar;116(3):312-6. Epub 2009 Nov 3.
- Weber B, Lortholary A, Mayer F, **Bourgeois H**, Orfeuvre H, Combe M, Platini C, Cretin J, Fric D, Paraiso D, Pujade-Lauraine E. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. *Anticancer Res*. 2009 Oct;29(10):4195-200.
- Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, **Dupuis O**, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMO2 Study. *J Clin Oncol*. 2009 Dec 1;27(34):5727-33. Epub 2009 Sep 28.



CLINIQUE MÉDICALE VICTOR HUGO

Joly F, Petit T, Pautier P, Guardiola E, Mayer F, Chevalier-Place A, Delva R, Sevin E, Henry-Amar M, **Bourgeois H**. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. *Gynecol Oncol*. 2009 Dec;115(3):382-8. Epub 2009 Sep 20.

Lipton A, Steger GG, Figueroa J, Alvarado C, **Solal-Celigny P**, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. *Clin Cancer Res*. 2008 Oct 15;14(20):6690-6.

Azria D, Auvray H, Barillot I, Baumann P, Benyoucef A, Bons-Rosset F, Bontemps P, Bourgier C, Breton-Callu C, Cowen D, Cretin J, Delalande B, **Denis F**, Ellis S, Gaci Z, Hannoun-Lévy JM, Hasbini A, Hennequin C, Lagrange JL, Lartigau E, Latorzeff I, Le Blanc-Onfroy M, Lecouillard I, Lemanski C, Levy C, Maingon P, Marchal C, Monnier A, Pradier O, Racadot S, Romestaing P, Serin D, Simon JM, Teysier E, Tallet A, Tolédano A, Belkacémi Y. [Ductal carcinoma in situ: role of the boost]. *Cancer Radiother*. 2008 Nov;12(6-7):571-6. Epub 2008 Aug 13. Review. French.

Marcus R, Imrie K, **Solal-Celigny P**, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. *J Clin Oncol*. 2008 Oct 1;26(28):4579-86. Epub 2008 Jul 28.

Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, Brousse N, Feugier P, Tilly H, **Solal-Celigny P**, Coiffier B. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. *J Clin Oncol*. 2008 Jul 20;26(21):3614-20. Epub 2008 Jun 16.

Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M, Jacob JH. Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study. *Oncology*. 2007;73(3-4):169-76. Epub 2008 Apr 16.

Cartron G, Ohresser M, Salles G, **Solal-Celigny P**, Colombat P, Watier H. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment. *Ann Oncol*. 2008 Aug;19(8):1485-7. Epub 2008 Apr 11.

Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, Lledo G, **Dupuis O**, Huguet F, Touboul E, Balosso J, Louvet C. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. *J Clin Oncol*. 2008 Mar 1;26(7):1080-5.

Beneton M, Chapet S, Blasco H, Giraudeau B, Boisdrion-Celle M, Deporte-Fety R, **Denis F**, Narcisso B, Calais G, Le Guellec C. Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy. *Br J Clin Pharmacol*. 2007 Nov;64(5):613-21. Epub 2007 Jun 19.

Solal-Celigny P. What is the optimal prognostic tool for the assessment of patients with newly diagnosed follicular lymphoma? *Leuk Lymphoma*. 2007 Mar;48(3):452-3. No abstract available.

Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R, Tourani J, Brain E, Nguyen L, Lefresne F, Puozzo C. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. *Cancer Chemother Pharmacol*. 2007 Aug;60(3):407-13.

Colas S, Mahéo K, **Denis F**, Goupille C, Hoinard C, Champeroux P, Tranquart F, Bougnoux P. Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. *Clin Cancer Res*. 2006 Oct 1;12(19):5879-86.

Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, **Bourgeois H**, Paraiso D, Pujade-Lauraine E. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. *Ann Oncol*. 2007 Feb;18(2):263-8. Epub 2006 Nov 15.

Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, **Bourgeois H**, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. *J Natl Cancer Inst*. 2006 Aug 2;98(15):1036-45.



CLINIQUE MÉDICALE VICTOR HUGO

Feugier P, Van Hoof A, Sebban C, **Solal-Celigny P**, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol*. 2005 Jun 20;23(18):4117-26. Epub 2005 May 2.

Oudard S, Banu E, Beuzebec P, **Voog E**, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. *J Clin Oncol*. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

Reyes F, Lepage E, **Ganem G**, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H; Groupe d'Etude des Lymphomes de l'Adulte (GELA). ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. *N Engl J Med*. 2005 Mar 24;352(12):1197-205.

Rohatiner AZ, Gregory WM, Peterson B, Borden E, **Solal-Celigny P**, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA. Meta-analysis to evaluate the role of interferon in follicular lymphoma. *J Clin Oncol*. 2005 Apr 1;23(10):2215-23. Epub 2005 Jan 31.

Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, **Solal-Celigny P**, Offner F, Walewski J, Raposo J, Jack A, Smith P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood*. 2005 Feb 15;105(4):1417-23. Epub 2004 Oct 19.